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ABSTRACT
Transcription factor nuclear factor erythroid 2–related factor 2 (Nrf2)
regulates multiple biologic processes, including hepatic lipid me-
tabolism. Estrogen exerts actions affecting energy homeostasis,
including a liver fat-lowering effect. Increasing evidence indicates
the crosstalk between these two molecules. The aim of this study
was to evaluate whether Nrf2 modulates estrogen signaling in
hepatic lipid metabolism. Nonalcoholic fatty liver disease (NAFLD)
was induced in wild-type andNrf2-null mice fed a high-fat diet and
the liver fat-lowering effect of exogenous estrogen was sub-
sequently assessed.We found that exogenous estrogen eliminated
49% and 90% of hepatic triglycerides in wild-type and Nrf2-null
micewithNAFLD, respectively. This observation demonstrates that
Nrf2 signaling is antagonistic to estrogen signaling in hepatic fat
metabolism; thus, Nrf2 absence results in striking amplification of
the liver fat-lowering effect of estrogen. In addition, we found the
association of trefoil factor 3 and fatty acid binding protein 5 with
the liver fat-lowering effect of estrogen. In summary, we identified
Nrf2 as a novel and potent inhibitor of estrogen signaling in hepatic
lipid metabolism. Our finding may provide a potential strategy to
treat NAFLD by dually targeting Nrf2 and estrogen signaling.
Introduction
Estrogen, via its nuclear receptors estrogen receptor (ER) a
and ERb and membrane-bound ER, regulates energy homeo-
stasis in addition to its well established essential roles in
reproduction (Barros and Gustafsson, 2011; Xu et al., 2011).
Many studies have demonstrated that, irrespective of gender,
estrogen (predominantly relying on ERa) exerts body weight-
lowering, adiposity-lowering, and antidiabetic effects through
systematic and tissue-specific mechanisms in both rodents
and humans. The pivotal roles of estrogen signaling in the
metabolic network were thoroughly reviewed by several
groups recently (Roepke, 2009; Barros and Gustafsson, 2011;
Mauvais-Jarvis et al., 2013; Frank et al., 2014; Kim et al.,
2014; Palmer and Clegg, 2015). The liver is one of the key
organs coordinately controlling energy homeostasis, including
lipid metabolism. Hepatic estrogen signaling is critical for
maintaining lipid homeostasis in the liver (Han et al., 2014;
Shen and Shi, 2015). Nonalcoholic fatty liver disease (NAFLD),
primarily manifested by excessive fat accumulation in hepato-
cytes, has become the most common chronic liver disease
worldwide (Demir et al., 2015). A number of studies consistently
showed that estrogen displays a fat-lowering effect by pre-
sumably inhibiting lipogenesis and promoting lipolysis in the
liver in a variety of animal models, including genetically
manipulated mice, ovariectomized rodents, spontaneous
obese mice, and rodents with diet-induced metabolic syn-
drome (Jones et al., 2000; Hewitt et al., 2004; Gao et al., 2006;
Bryzgalovaet al., 2008;Lundholmetal., 2008;Pedrametal., 2013;
Zhang et al., 2013a; Han et al., 2014). However, the mechanisms
behind those observations, especially how the fat-lowering action
of estrogen is modulated in the liver, remain elusive.
As a leucine zipper motif-containing transcription factor,
nuclear factor erythroid 2–related factor 2 (Nrf2) essentially
mediates the cellular response against redox stress. Its target
genes include those encoding cytoprotective proteins, such as
detoxifying enzymes, glutathione synthesis enzymes, and
antioxidant proteins, thereby positively or negatively contrib-
uting to carcinogenesis, drug resistance, and many degener-
ative diseases (Dodson et al., 2015; Huang et al., 2015; Suzuki
and Yamamoto, 2015; Tebay et al., 2015). Depending on a dis-
ease condition, activation or suppression of Nrf2 is believed to
be a promising therapeutic strategy. In addition, Nrf2 regu-
lates carbohydrate and lipid metabolism, participating in the
development and progression of NAFLD despite contradictory
findings in the literature (Chambel et al., 2015; Tebay et al.,
2015).
Several lines of evidence suggest a unidirectional positive or
negative effect of estrogen signaling on Nrf2 activity in a cell
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type– or tissue–dependent manner. Estrogen stimulates Nrf2
activation in epithelial cells of the mammary gland, cerebral
nerve tissue, primary myocardial cells, umbilical vein endo-
thelial cells, ovarian epithelial carcinoma, and breast cancer
cells (Liao et al., 2012; Yu et al., 2012; Zhang et al., 2013b;
Gorrini et al., 2014; Meng et al., 2014; Wu et al., 2014). In
contrast, estrogen potently inhibits the activities of Nrf2
target proteins (glutathione-S-transferase and quinone re-
ductase), specifically in the uterus, possibly via its ligand-
dependent interaction with Nrf2 (Ansell et al., 2004, 2005).
The liver highly expresses both ERa and Nrf2, both of which
are involved in hepatic lipid metabolism (Chan et al., 1996;
Kuiper et al., 1997). We were interested in whether there is a
connection between Nrf2 and estrogen signaling in NAFLD.
In our studies, NAFLD was induced in wild-type and Nrf2-
null mice fed a high-fat diet (HFD), which was followed by an
estradiol-17b (E2) treatment regimen. We found that the lack
of Nrf2 results in a marked increase in hepatic ERa basal
expression and striking amplification of the liver fat-lowering
effect of E2. These findings demonstrate Nrf2 as a new and
potent negative modulator of estrogen signaling in hepatic
lipid metabolism.
Materials and Methods
Animal Care andUse. Nrf21/1andNrf22/2malemice of aC57BL6/
129SV mixed background were used for the study (Chan et al., 1996).
Standard rodent chow and drinking water were provided ad libitum
throughout the experiment. To induce NAFLD, mice were given a HFD
(TD.88137; Harlan Laboratories, Madison, WI) for 16 weeks. Afterward,
mice received vehicle (sesame oil), E2 (25 mg/mouse; Sigma-Aldrich, St.
Louis, MO) (Bourassa et al., 1996), progesterone (1 mg/mouse; Sigma-
Aldrich) (Walter et al., 2005), or a combination of these two steroid
hormones (25 mg E2 and 1 mg progesterone/mouse) subcutaneously
once daily for 3 weeks, while they were continuously fed the HFD.
Animals were euthanized 4 hours after the last dosing. All of the
animal experiments were conducted in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals. Protocols for the care and use of animals were approved by
the Indiana University–Purdue University Indianapolis Animal Care
and Use Committee.
Histology and Immunohistochemistry. Liver specimens em-
bedded in paraffin were sliced at 5-mm thickness and stained with
hematoxylin and eosin to examine liver histology. Liver sections were
subjected to immunostainingwith a fatty acid binding protein 5 (FABP5)
antibody (GTX12109; GeneTex, Irvine, CA) or a trefoil factor 3 (TFF3)
primary antibody (TFF331-A; Alpha Diagnostic, San Antonio, TX)
according to the manufacturer’s instructions. Optimal cryo embedding
medium-embedded liver specimens were cut into 10-mm thickness and
stained with Oil Red O to visualize intracellular lipid droplets.
Measurement of Liver Lipid Content. Hepatic triglycerides,
total cholesterol, and free fatty acids were quantified using commer-
cially available kits (ab65336, ab65359, and ab65341; Abcam, Cam-
bridge, MA) according to the manufacturer’s instructions.
Mouse Fatty Liver RT2 Profiler Polymerase Chain Reaction
Array. Total RNA was extracted from the livers using TRIzol regent
(Invitrogen, Carlsbad, CA). cDNAswere synthesized from 500 ng total
RNA for each sample using the RT2 First-Strand Kit (330401; Qiagen,
Valencia, CA). The Mouse Fatty Liver RT2 Profiler PCR Array, which
profiles the expression of 84 key genes involved in the mechanisms of
NAFLD and hepatic insulin resistance, and RT2 SYBR Green ROX
qPCR Master Mix were purchased form Qiagen (PAMM-157Z,
330520). The amplification reactions were carried out with the ABI
Prism 7900 sequence detection system (Applied Biosystems, Foster
City, CA). Fold changes in gene expression between different groups
were calculated using the comparative threshold cycle method in the
PCR Array Data Analysis template from Qiagen.
Quantitative Real-Time Polymerase Chain Reaction. Total
RNA was isolated from each frozen liver using TRIzol reagent
according to the manufacturer’s protocol (Invitrogen). cDNAs were
synthesized from 1 mg total RNA of each sample using a Verso cDNA
Kit (Thermo Scientific, Rockford, IL), diluted four times with water,
and subjected to quantitative real-time polymerase chain reaction
(PCR). TaqMan Universal PCR Master Mix and the primers and
TaqMan MGB probes of mouse Nrf2 (Mm00477786_m1), NAD(P)H:
quinone oxidoreductase (NQO)-1 (NQO-1) (Mm01253561_m1), ERa
(Mm00433149_m1), ERb (Mm00599821_m1), TFF3 (Mm00495590_m1),
FABP5 (Mm00783731_s1), and albumin (Mm00802090_m1) were pur-
chased from Applied Biosystems. The amplification reactions were carried
out with the ABI Prism 7900 sequence detection system (Applied
Biosystems) with initial hold steps (50°C for 2 minutes followed by 95°C
for 10 minutes) and 40 cycles of a two-step PCR (92°C for 15 seconds
and 60°C for 1 minute). The comparative threshold cycle method was
used for the relative quantification of the amount of mRNA in each
sample normalized to the albumin transcript levels.
Western Blot Analysis. Liver homogenates (10 mg) were sepa-
rated by PAGE under reducing conditions. Proteins from the gels were
electrophoretically transferred to polyvinylidene difluoridemembranes.
Antibodies against NQO-1 (ab80588; Abcam), ERa (SC-514910; Santa
Cruz Biotechnology, Santa Cruz, CA), FABP5 (GTX12109; GeneTex),
and glyceraldehyde-3-phosphate dehydrogenase (SC-130656; Santa Cruz
Biotechnology) were used as probes. Immune complexes were detected
using the enhanced chemiluminescence system (Pierce, Rockford, IL).
Statistical Analysis. Data are shown as means6 S.D. Statistical
analysis was performed using a one-way analysis of variance or t test.
Significant differences were defined when P , 0.05.
Results
Nrf2 Absence Results in a Strikingly Enhanced Liver
Fat-Lowering Effect of Estrogen in Mice with NAFLD.
To determine whether Nrf2 modulates estrogen signaling in
hepatic fat metabolism, we fed adult male wild-type andNrf2-
null mice a HFD for 4 months to induce NAFLD. Afterward,
we treated mice with both genotypes with vehicle, E2, pro-
gesterone, or a combination of E2 and progesterone once per
day for 3weeks. During the steroid hormone treatment period,
mice were continuously fed the HFD. Progesterone often
exerts opposite effects to estrogen in many tissues (Diep
et al., 2015). Hence, progesterone served as a potential
negative control, whereas the combination of the two steroid
hormones was used as a potential antagonistic control.
We first examined the liver size and hepatic histology. We
found that Nrf2 absence caused a slight but significant
reduction in liver-to-body weight ratio in mice fed a normal
chow, as reported (Huang et al., 2010; Zou et al., 2014) (Fig. 1).
The HFD induced liver enlargement and massive hepatic fat
accumulation in both wild-type and Nrf2-null mice in the
vehicle control group (Figs. 1 and 2). Compared with the
vehicle control, exogenous estrogen resulted in deceases in
liver size and hepatic fat deposition in both genotype groups of
mice, exerting a liver fat-lowering effect, as demonstrated by
others (Gao et al., 2006; Bryzgalova et al., 2008; Han et al.,
2014) (Figs. 1 and 2). Notably, histologic assessment revealed
that this effect was evidently enhanced when Nrf2 was
lacking, which was manifested by a further reduction in liver
fat accumulation in Nrf2-null mice (Fig. 2). This finding
indicates that Nrf2 counteracts with estrogen signaling in
hepatic lipid metabolism. Relative to the vehicle control,
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irrespective of genotype, exogenous progesterone did not
overtly affect liver size and fat deposition (Figs. 1 and 2).
However, regardless of genotype, the liver fat-lowering effect
of estrogen was largely prevented in the estrogen and pro-
gesterone combination treatment group (Fig. 2), indicating
that progesterone antagonizes the action of estrogen in
eliminating hepatic fat content. Together, our findings dem-
onstrate that Nrf2 negatively modulates estrogen signaling in
NAFLD.
To further demonstrate the above findings, we performed
Oil Red O staining on liver sections to visualize fat deposition.
As a result, compared with the vehicle control, estrogen
administration reduced liver fat staining in wild-type mice
and, strikingly, almost diminished that in Nrf2-null mice (Fig.
3A). We subsequently quantified hepatic lipid contents.
Relative to normal chow, the HFD induced excessive accumu-
lation of triglycerides, total cholesterol, and free fatty acids in
the liver, which were equivalent quantitatively between wild-
type and Nrf2-null mice (Fig. 3B). In wild-type mice, relative
to the vehicle control, exogenous estrogen decreased hepatic
triglycerides by 49% and free fatty acids by 25% but did not
significantly affect total cholesterol (Fig. 3B). When Nrf2 was
absent, exogenous estrogen reduced hepatic triglycerides by
90%, free fatty acids by 54%, and total cholesterol by 37% (Fig.
3B). The data together demonstrate that the liver fat-lowering
effect of estrogen is drastically heightened because of the lack
of Nrf2, indicating that Nrf2 is antagonistic to estrogen
signaling in hepatic fat metabolism.
Nrf2 Absence Causes a Marked Increase in Exoge-
nous Estrogen-Induced Hepatic Estrogen Signaling in
Mice with NAFLD. We evaluated hepatic Nrf2 signaling by
assessing the mRNA expression of Nrf2 and its typical target
gene NQO-1 in the liver (Chan et al., 2001) (Fig. 4A). As
expected, in normal chow-fed mice, Nrf2 deficiency led to a
reduction in the basal level of hepatic NQO-1 mRNA. HFD
feeding highly activated Nrf2 in wild-type mice, relative to
normal chow feeding, which was manifested by 8-fold and
6-fold upregulation in Nrf2 and NQO-1 gene expression,
respectively. As a result of Nrf2 genetic deletion, NQO-1
mRNA did not respond to the HFD. The data demonstrate
that NQO-1 expression is solely controlled by Nrf2 in this
disease condition, reliably reflecting Nrf2 activity. In wild-
type mice with NAFLD, compared with the vehicle control,
estrogen administration did not significantly alter Nrf2, while
marginally increased NQO-1, transcript level. The data in-
dicate that exogenous estrogen slightly increased HFD-
induced activation of hepatic Nrf2. In addition, excessive
estrogen did not significantly influence Nrf2-dependent regu-
lation of hepaticNQO-1 gene in this disease. This observation
indicates that estrogen signaling does not independently
control NQO-1 mRNA expression. Furthermore, we showed
that NQO-1 mRNA expression was consistent with its protein
expression in the liver in various conditions (Fig. 4B). Taken
together, we demonstrate that hepatic Nrf2 is highly activated
in NAFLD and exogenous estrogen can somewhat further
increase hepatic Nrf2 activity in this condition.
We next assessed hepatic ER signaling by evaluating the
expression of ERa, ERb, and TFF3 genes (Fig. 4A) and ERa
protein (Fig. 4B) in the liver. TFF3 is an estrogen-responsive
gene; thus, its mRNA expression was used to estimate ER
activity (May and Westley, 1997; Gruvberger et al., 2001). In
normal chow-fed mice, Nrf2 deficiency caused a 6.5-fold
increase in hepatic ERa mRNA expression. Both wild-type
and Nrf2-null mice fed the normal chow displayed variable
expression of hepatic ERa protein. Notably, in normal chow-
fed mice, Nrf2 absence resulted in a 4.5-fold elevation in the
hepatic TFF3 mRNA level, indicating higher ERa activity.
This finding suggests that Nrf2 may be a suppressor of ERa
signaling in the homeostasis condition. Compared with nor-
mal chow feeding, HFD feeding increased and reduced hepatic
ERa mRNA expression in wild-type and Nrf2-null mice,
respectively, resulting in equivalent ERa mRNA levels be-
tween the two genotypes. Relative to normal chow feeding,
HFD feeding induced overt increases in hepatic ERa protein
expression in both wild-type and Nrf2-null mice. Taken
together, these data indicate that mRNA and protein of
hepatic ERa differentially respond to the disease state in
their expression. Compared with normal chow feeding, HFD
feeding did not affect Nrf2-dependent basal TFF3 transcript
expression, showing that HFD does not alter Nrf2-dependent
basal activity of hepatic ERa. Remarkably, relative to the
vehicle control in wild-type mice, E2 administration elevated
hepatic TFF3 mRNA expression by 122-fold in the presence of
Nrf2 and by 480-fold in the absence of Nrf2. Immunohisto-
chemical analysis showed that hepatic TFF3 protein was
mainly induced in hepatocytes (Fig. 4C). The data demon-
strate that the lack of Nrf2 leads to an astonishing enhance-
ment of exogenous estrogen-induced hepatic ER signaling in
NAFLD. Collectively, these findings demonstrate that Nrf2
antagonizes hepatic estrogen signaling and Nrf2 deficiency
thereby results in amplification of the clearing effect of
exogenous estrogen on liver fat. In addition, the hepatic
TFF3 level positively correlates with the liver fat-lowering
effect of estrogen. ERb mRNA was barely detected across the
Fig. 1. Liver-to-body weight ratios. Adult male wild-type (Nrf2+/+) and
Nrf2-null (Nrf22/2) mice were fed a HFD for 16 weeks. Afterward, vehicle
(sesame oil), E2 (, 625 mg/kg), progesterone (P, 25 mg/kg), or a combination
of these two steroids (625 mg/kg E2 and 25 mg/kg progesterone) was
injected subcutaneously once daily for 3 weeks. At 4 hours after the last
dosing, mice were weighed and then euthanized for sample collection.
Nrf2+/+ and Nrf22/2 mice fed a normal chow served as homeostasis
controls. The liver-to-body weight ratioswere calculated and are shown. *P,
0.05, compared with normal chow-fedNrf2+/+ mice; #P, 0.05, comparedwith
normal chow-fed Nrf22/2mice; ¥P , 0.05, compared as indicated. n = 5.
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samples (data not shown), indicating that ERa dominantly
mediates the action of estrogen in the liver.
FABP5 Is Induced in anNrf2- andExogenous Estrogen-
Dependent Manner in Mice with NAFLD. To gain further
insight into the above findings, we analyzed hepatic expression of
84 key genes involved in themechanisms of NAFLD and hepatic
insulin resistance by a Mouse Fatty Liver RT2 Profiler PCR
Array in both genotype groups of mice with NAFLD (Supple-
mental Table 1). Surprisingly, we found that only FABP5
exhibited bothNrf2- and exogenous estrogen-dependent changes.
The datawere validated by quantitative real-time PCR (Fig. 5A).
In normal chow-fed mice, Nrf2 deficiency resulted in a 6.5-fold
increase in hepatic FABP5 mRNA expression. The data indicate
that Nrf2 suppresses FABP5 basal expression in the liver in the
homeostasis condition. Compared with normal chow feeding,
HFD feeding suppressed hepatic FABP5 gene expression in both
genotype groups of mice. Compared with vehicle controls, E2
treatment led to increases in hepatic FABP5mRNA irrespective
of genotype in mice with NAFLD. Notably, the magnitude of
exogenous estrogen-induced elevation of hepatic FABP5 tran-
scription in Nrf2-null mice was 2.4-fold higher than that in wild-
typemice.Western blotting and immunohistochemical analyses
of hepatic FABP5 protein further demonstrated the finding at
the protein level and revealed its expression in hepatocytes
(Figs. 4B and 5B). The data indicate that 1) FABP5 is a novel
estrogen-responsive gene in the liver, 2) Nrf2 limits exogenous
estrogen-induced elevation of hepatic FABP5, and 3) FABP5
positively correlates with the liver fat-lowering effect of
estrogen.
Discussion
These studies identified Nrf2 as a potent suppressor of
estrogen signaling in the liver. We provided two pieces of
evidence to support our notion. First, in a homeostasis
condition, Nrf2 deficiency resulted in enhanced hepatic estro-
gen signaling, manifested by elevated expression of its target
gene TFF3. Second, in NAFLD, the lack of Nrf2 led to
drastically increased activation of hepatic estrogen signaling
by E2, reflected by a markedly elevated TFF3 induction and
highly enhanced liver fat-lowering effect of E2. The exact
mechanism underlying the crosstalk between Nrf2 and estro-
gen signaling must be further investigated. It has been
reported that Nrf2 directly interacts with ERa at the protein
Fig. 2. Histologic assessments of liver sections.
Livers were collected from the experiment described
in Fig. 1. Formalin-fixed and paraffin-embedded
liver sections were stained with hematoxylin and
eosin and were visualized at low magnification (A)
and high magnification (B). Original magnification,
100 in A; 400 in B.
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level in the uterus (Ansell et al., 2004, 2005). Xie et al. revealed
a feedback mechanism between Nrf2 and estrogen in liver
ischemia and reperfusion (I/R) Guo et al., 2015. I/R-induced
Nrf2 activation directly upregulates estrogen sulfotransferase
and in turn increases estrogen breakdown, limiting Nrf2
activity and gender-dependently affecting I/R injury (Guo
et al., 2015). In addition, the crosstalk of Nrf2 signaling with
the PTEN-GSK-3-b-TrCP pathway and the p62-mediated
autophagy pathway has been demonstrated (Komatsu et al.,
2010; Ni et al., 2014; Rojo et al., 2014; Taguchi et al., 2014).
Han et al. (2014) uncovered an ERa/liver X receptor (LXR)/
sterol regulatory element-binding protein (SREBP) 1 pathway
modulating hepatic lipid metabolism (Han et al., 2014). They
demonstrate that ERa interacts with LXR and inhibits LXR-
dependent transcription of SREBP1, a critical fatty acid
biosynthesis regulator, contributing to estrogen’s liver fat-
lowering effect. In our studies, we found that estrogen
treatment did not significantly alter hepatic SREBP1 expres-
sion compared with Nrf21/1 and Nrf22/2 HFD-fed mice
(Supplemental Table 1). This finding suggests that Nrf2-
dependent enhancement of the liver fat-lowering effect of
estrogen may not be via this ERa/LXR/SREBP1 pathway.
Here, we created a novel connection between the Nrf2- and
ERa-mediated signaling pathway in lipid metabolism. We
believe that our finding will provide a critical mechanistic
aspect in understanding liver health and disease, because
these two molecules are all essential for maintaining liver
homeostasis.Moreover, we demonstrate a potential therapeutic
strategy of dual targets (inhibiting Nrf2 and activating ERa) for
NAFLD, which has emerged as the most common chronic liver
disorder without a clinical cure in developed countries (Sanyal,
2015).
Our studies revealed the positive correlation of TFF3 with
the liver fat-lowering effect of estrogen. We observed that the
amplification of the liver fat-lowering effect of E2 in Nrf2-null
mice with NAFLD was accompanied by further increased
hepatic TFF3 induction. TFF family members including
TFF1, TFF2, and TFF3 are secretory peptides without a known
receptor (Busch and Dünker, 2015). Information regarding
their expression, regulation, and function is expanding. TFF3
is expressed along the gastrointestinal tract, promotes wound
healing of the gastrointestinal epithelium, and is associated
with gastroadenocarcinoma progression (Xiao et al., 2015). It is
also expressed in pancreatic b cells and oxytocin-secreting
neurons in the hypothalamus, related to cell growth and
learning and memory (Jagla et al., 2000; Fueger et al., 2008;
Shi et al., 2012). This peptide is induced in biliary duct
epithelial cells in biliary diseases (Srivatsa et al., 2002; Nozaki
et al., 2004; Sasaki et al., 2007; Jiang et al., 2010). The TFF3
genemaps to the Obq4 obesity quantitative trait locus, which is
highly associated with total calorie intake; indeed, the expres-
sion of Obq4 in the intestine is regulated by food intake (Kumar
and Smith Richards, 2008; Ge et al., 2015). Hepatic TFF3
expression is increased in hepatic steatosis and decreased in db/
db mice and mice with diet-induced obesity (DIO), suggesting
its involvement in lipid metabolism (Guillén et al., 2009; Xue
et al., 2013). Adenovirus-mediated 5.5-fold overexpression of
mouse TFF3 in the liver reduces blood glucose and improves
glucose tolerance in db/db mice and ameliorates insulin re-
sistance in DIOmice (Xue et al., 2013). Adeno-associated virus-
mediated overexpression of human TFF3, reaching 900 ng/ml
in 2 weeks after virus infection, improves glucose tolerance in
Fig. 3. Liver fat assessments. Livers were harvested from the experiment
indicated in Fig. 1. (A) Oil Red O staining of liver fat. Frozen liver sections
were stained with Oil Red O. Liver fat was stained red. (B) Quantification
of liver fat contents. Frozen livers were used for measuring the concen-
trations of hepatic triglycerides, free fatty acids, and total cholesterol with
various commercially available kits. *P , 0.05. n = 5.
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DIO mice without affecting body weight, fasting insulin, and
levels of triglycerides, cholesterol, and leptin in the blood (Ge
et al., 2015). These two studies highlighted the critical role of
TFF3 in maintaining glucose homeostasis. However, it is not
clear whether TFF3 overexpression affects hepatic lipid con-
tents and whether human TFF3 is equipotent to mouse TFF3 in
mice. Thus, whether TFF3 regulates hepatic lipid metabolism
and mediates the liver fat-lowering effect of estrogen warrants
further investigation.
Our studies also showed the association of FABP5 with the
liver fat-lowering effect of estrogen. In mice with NAFLD,
compared with the vehicle control, exogenous E2 increased
hepatic FABP5 expression in wild-type mice and further
increased its expression in Nrf2-null mice. It is evident that
the level of FABP5 expression is positively correlated with the
liver fat-lowering effect of estrogen. FABP5 belongs to a family
of intracellular fatty acid binding proteins with tissue-specific
distribution and functions. They bind unesterified long-chain
fatty acids and regulate lipidmetabolism (fatty acid transport,
metabolism, and storage), inflammation, and energy homeo-
stasis (Thumser et al., 2014; Hotamisligil and Bernlohr, 2015).
FABP5 has been shown to interact with nuclear receptor
Fig. 4. (A) mRNA expression of hepatic Nrf2, NQO-1, ERa, and TFF3. Total
RNA was extracted from each liver collected from the experiment illustrated in
Fig. 1. Hepatic mRNA expression of the genes indicated was quantified with
quantitative real-time PCR. The hepatic mRNA level of each gene in normal
chow-fed Nrf2+/+ mice was set to 1. *P , 0.05, compared with normal chow-fed
Nrf2+/+ mice; #P , 0.05, compared with normal chow-fed Nrf22/2 mice; ¥P ,
0.05, compared betweenNrf2+/+ andNrf22/2mice. n = 5. (B) Protein expression
of hepatic NQO-1, ERa, and FABP5. Total liver lysates were prepared from the
livers collected from the experiment described in Fig. 1. Western blotting was
performed with the antibodies against the proteins indicated. The lanes
represent samples prepared from individual mice. (C) Hepatic expression and
distribution of TFF3 protein. Formalin-fixed and paraffin-embedded liver
sections prepared from the experiment indicated in Fig. 1 were subjected to
immunostaining with a TFF3 antibody. TFF3 protein was stained dark brown.
Fig. 5. Nrf2- and estrogen-dependent induction of FABP5 in the liver. (A)
Hepatic expression of FABP5 mRNA. Total RNA samples prepared from
the experiment described in Fig. 4 were used for evaluating the transcript
levels of hepatic FABP5 with quantitative real-time PCR. Hepatic mRNA
expression of the gene in normal chow-fed Nrf2+/+ mice was set to 1. *P ,
0.05, compared with normal chow-fed Nrf2+/+ mice; #P , 0.05, compared
with normal chow-fed Nrf22/2mice; ¥P , 0.05, compared between Nrf2+/+
andNrf22/2mice. n = 5. (B) Hepatic expression and distribution of FABP5
protein. Formalin-fixed and paraffin-embedded liver sections prepared
from the experiment indicated in Fig. 1 were subjected to immunostaining
with a FABP5 antibody. FABP5-expressing cells were stained dark brown.
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peroxisome proliferator-activated receptor, exhibiting proper-
ties of anti-inflammation and antioxidative stress (Berger
et al., 2012; Gally et al., 2013). Overexpression of FABP5 in
adipose tissue results in increased lipolysis, decreased fat
mass, and potentiated insulin resistance (Hertzel et al., 2006).
In the liver, FABP5 displays an anti-inflammatory action by
regulating macrophage phenotypes (Moore et al., 2015).
Consistent with a report showing that FABP5 is negatively
regulated by Nrf2 in normal and fatty livers (Chartoumpekis
et al., 2013), we additionally revealed that hepatic FABP5
positively responds to estrogen signaling in NAFLD. Notably,
we found that FABP5 is the only one exhibiting both Nrf2- and
E2-dependant alterations among the examined 84 genes that
are associated with fat metabolism and insulin signaling.
Taken together, these findings suggest an Nrf2/ERa/FABP5
regulatory pathway that controls hepatic lipid homeostasis.
Hence, the function of FABP5 in liver lipid metabolism needs
further investigation.
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